Therefore, the final result of blocking the CD28/CTLA-4/B7 pathway in EAE/MS may depend on the relative strength of the CTLA-4 and CD28 signals as well as the blocking time point (61). This evidence concerns the gene CD80 and myeloid sarcoma.